2019冠状病毒病疫苗在老年人中的意外疗效。
Unanticipated efficacy of SARS-CoV-2 vaccination in older adults.
作者信息
Pawelec Graham, McElhaney Janet
机构信息
Department of Immunology, University of Tübingen, Tübingen, Germany.
Health Sciences North Research Institute, Sudbury, Ontario, Canada.
出版信息
Immun Ageing. 2021 Feb 17;18(1):7. doi: 10.1186/s12979-021-00219-y.
Abstract
The rapidity with which vaccines against COVID-19 have been developed and tested is unprecedented. As classically the case with randomized clinical trials, many studies excluded older adults. However, given the early realisation that senior citizens were most highly susceptible to COVID, older individuals have been included in licensing trials under these unusual conditions. The recently published results from the Comirnaty Vaccine (BNT162b) trial unexpectedly documented that vaccine efficacy was equally exceptionally high in older and younger adults. These extremely encouraging trial results with a neoantigen vaccine may suggest the beginning of a paradigm shift in our view of the impact of immunosenescence on vaccination against novel infectious diseases.
摘要
针对新冠病毒的疫苗研发和测试速度之快是前所未有的。与传统的随机临床试验一样，许多研究将老年人排除在外。然而，鉴于人们很早就认识到老年人对新冠病毒最为易感，在这些特殊情况下，老年人已被纳入疫苗许可试验。最近公布的辉瑞疫苗（BNT162b）试验结果意外地表明，该疫苗在老年人和年轻人中的疗效同样异常高。这些关于新抗原疫苗的极其令人鼓舞的试验结果可能表明，我们对免疫衰老对新型传染病疫苗接种影响的看法开始发生范式转变。
相似文献
1
Unanticipated efficacy of SARS-CoV-2 vaccination in older adults.2019冠状病毒病疫苗在老年人中的意外疗效。
Immun Ageing. 2021 Feb 17;18(1):7. doi: 10.1186/s12979-021-00219-y.
2
Can an effective SARS-CoV-2 vaccine be developed for the older population?能否为老年人群研发出有效的新冠病毒疫苗？
Immun Ageing. 2020 Apr 11;17:8. doi: 10.1186/s12979-020-00180-2. eCollection 2020.
3
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.新型冠状病毒灭活疫苗在安全性和免疫原性方面的效果：两项随机临床试验的中期分析。
JAMA. 2020 Sep 8;324(10):951-960. doi: 10.1001/jama.2020.15543.
4
Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.在新冠疫情期间使用卡介苗增强医护人员的非特异性防护：丹麦一项随机对照试验研究方案的结构化总结
Trials. 2020 Sep 17;21(1):799. doi: 10.1186/s13063-020-04714-3.
5
COVID-19 pandemic predictions using the modified Bateman SIZ model and observational data for Heidelberg, Germany: Effect of vaccination with a SARS-CoV-2 vaccine, coronavirus testing and application of the Corona-Warn-App.使用改进的贝特曼易感-感染-恢复模型及德国海德堡观测数据进行的COVID-19大流行预测：接种SARS-CoV-2疫苗、冠状病毒检测及应用新冠警示应用程序的影响
Int J Clin Pharmacol Ther. 2020 Aug;58(8):417-425. doi: 10.5414/CP203846.
6
Impact of Microbiota: A Paradigm for Evolving Herd Immunity against Viral Diseases.微生物组的影响：针对病毒病不断发展群体免疫的范例。
Viruses. 2020 Oct 10;12(10):1150. doi: 10.3390/v12101150.
7
Principles and new perspectives in the vaccination against SARS-CoV-2 virus.SARS-CoV-2 病毒疫苗接种的原则和新视角。
Cas Lek Cesk. 2020 Winter;159(7-8):298-302.
8
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.CEPI/BC 2020 年 3 月 12-13 日会议共识总结报告：评估 COVID-19 疫苗引起疾病增强的风险。
Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25.
9
Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination.与美国成年人接受 COVID-19 疫苗意愿相关的因素。
JAMA Netw Open. 2020 Oct 1;3(10):e2025594. doi: 10.1001/jamanetworkopen.2020.25594.
10
A COVID-19 vaccine-dare to dream.一种新冠疫苗——敢于梦想。
Br J Community Nurs. 2020 Dec 2;25(12):2-7. doi: 10.12968/bjcn.2020.25.12.598.
引用本文的文献
1
Nucleic acid vaccines: innovations, efficacy, and applications in at-risk populations.核酸疫苗：创新、疗效及在高危人群中的应用
Front Immunol. 2025 May 14;16:1584876. doi: 10.3389/fimmu.2025.1584876. eCollection 2025.
2
Comparison of inflammatory mediator cytokine responses to inactivated virus platform COVID-19 vaccines between elderly and young adult populations.老年人与年轻成年人对灭活病毒平台新冠疫苗的炎症介质细胞因子反应比较。
Narra J. 2024 Dec;4(3):e1380. doi: 10.1042/narra.v4i3.1380. Epub 2024 Nov 12.
3
SARS-CoV-2 infection establishes a stable and age-independent CD8 T cell response against a dominant nucleocapsid epitope using restricted T cell receptors.SARS-CoV-2 感染利用受限的 T 细胞受体建立了针对主要核衣壳表位的稳定且与年龄无关的 CD8 T 细胞应答。
Nat Commun. 2023 Oct 23;14(1):6725. doi: 10.1038/s41467-023-42430-z.
4
Aging and chronic inflammation: highlights from a multidisciplinary workshop.衰老与慢性炎症：多学科研讨会要点
Immun Ageing. 2023 Jun 8;20(1):25. doi: 10.1186/s12979-023-00352-w.
5
Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes.接种第三剂疫苗后，养老院老年居民的免疫原性较强，但抗体迅速衰减。
Nat Aging. 2023 Jan;3(1):93-104. doi: 10.1038/s43587-022-00328-3. Epub 2023 Jan 20.
6
Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection.在未接种疫苗的长期护理机构居民中，自然感染后能产生强大的 SARS-CoV-2 特异性和异源免疫应答。
Nat Aging. 2022 Jun;2(6):536-547. doi: 10.1038/s43587-022-00224-w. Epub 2022 May 30.
7
T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.养老院居民中初次接种和加强接种 SARS-CoV-2 信使 RNA 疫苗后的 T 细胞介导的反应。
J Am Med Dir Assoc. 2023 Feb;24(2):140-147.e2. doi: 10.1016/j.jamda.2022.11.024. Epub 2022 Dec 7.
8
One-Year Report of COVID-19 Impact on Geriatric Patients: a Bio-Psycho-Social Approach.新型冠状病毒肺炎对老年患者影响的一年期报告：生物心理社会视角
Can Geriatr J. 2022 Jun 1;25(2):212-221. doi: 10.5770/cgj.25.553. eCollection 2022 Jun.
9
BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19.BNT162b2、mRNA-1273 和 Sputnik V 疫苗在诱导免疫应答方面可相媲美，可预防 COVID-19 重症。
Front Immunol. 2022 Apr 13;13:797918. doi: 10.3389/fimmu.2022.797918. eCollection 2022.
10
COVID-19 pandemic over 2020 (withlockdowns) and 2021 (with vaccinations): similar effects for seasonality and environmental factors.2020 年（有封锁措施）和 2021 年（有疫苗接种）的 COVID-19 大流行：季节性和环境因素的影响相似。
Environ Res. 2022 May 15;208:112711. doi: 10.1016/j.envres.2022.112711. Epub 2022 Jan 13.
本文引用的文献
1
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
2
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.人类对 SARS-CoV-2 的预先存在和新产生的体液免疫。
Science. 2020 Dec 11;370(6522):1339-1343. doi: 10.1126/science.abe1107. Epub 2020 Nov 6.
3
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.两种基于 RNA 的新冠候选疫苗的安全性和免疫原性。
N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.
4
COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses.COVID-19 疫苗 BNT162b1 可引发人体抗体和 T1 T 细胞应答。
Nature. 2020 Oct;586(7830):594-599. doi: 10.1038/s41586-020-2814-7. Epub 2020 Sep 30.
5
The conundrum of human immune system "senescence".人类免疫系统“衰老”的难题。
Mech Ageing Dev. 2020 Dec;192:111357. doi: 10.1016/j.mad.2020.111357. Epub 2020 Sep 17.
6
Genetic and environmental determinants of human TCR repertoire diversity.人类T细胞受体库多样性的遗传和环境决定因素。
Immun Ageing. 2020 Sep 4;17:26. doi: 10.1186/s12979-020-00195-9. eCollection 2020.
7
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.未暴露于 SARS-CoV-2 人群中的选择性和交叉反应性 T 细胞表位。
Science. 2020 Oct 2;370(6512):89-94. doi: 10.1126/science.abd3871. Epub 2020 Aug 4.
8
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.SARS-CoV-2 反应性 T 细胞在健康供体和 COVID-19 患者中的研究。
Nature. 2020 Nov;587(7833):270-274. doi: 10.1038/s41586-020-2598-9. Epub 2020 Jul 29.
9
Frailty Is Associated With Increased Hemagglutination-Inhibition Titers in a 4-Year Randomized Trial Comparing Standard- and High-Dose Influenza Vaccination.在一项比较标准剂量和高剂量流感疫苗接种的4年随机试验中，虚弱与血凝抑制滴度升高相关。
Open Forum Infect Dis. 2020 Apr 24;7(5):ofaa148. doi: 10.1093/ofid/ofaa148. eCollection 2020 May.
10
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.COVID-19 疾病患者和未接触者体内针对 SARS-CoV-2 冠状病毒的 T 细胞反应的靶标。
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.
Zotero 插件